Adaptive Biotechnologies Shifts to Pure-Play MRD Diagnostics to Boost Profitability

Key Facts

1MRD revenue grew 49% year-over-year with sequencing gross margins exceeding 70%.

2The planned separation of Immune Medicine is expected to remove $6M in quarterly adjusted EBITDA losses.

In a move reflecting a strategic shift toward improving earnings quality and focusing on high-growth segments, Adaptive Biotechnologies announced its transition into a pure-play Minimal Residual Disease (MRD) diagnostics company. According to reports, the MRD diagnostics segment achieved robust year-over-year revenue growth of 49%, with sequencing gross margins exceeding 70%. This transition aims to clarify the company's financial profile by concentrating on its core diagnostics business.

The new strategy includes the planned separation of the Immune Medicine division, a step expected to remove $6 million in quarterly adjusted EBITDA losses. Per market data, this spin-off enhances operational efficiency and allows the company to direct resources toward the MRD segment, which is experiencing margin expansion, thereby reducing the financial drag previously imposed by the immune medicine unit.

Regarding market performance, ADPT stock stood at $24.18 (close July 30, 2026), with a daily high of $24.34 and a low of $22.07. Investors are closely monitoring the execution of the spin-off as a future catalyst, while the market also considers the impact of the Fed Interest Rate Decision on July 29, 2026, which held rates at 3.75%, affecting financing costs for the biotech sector.